Skip to main content

Table 3 Clinical studies of panobinostat (LBH589)

From: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents


Disease (pt. No.)


Recommended dose & response



Relapsed or refractory AML (15), MDS (1) and ALL(1).

Day 1 to 7 of a 21-day cycle

11.5 mg/m2



Cutaneous T-cell lymphoma(9)

Monday, Wednesday and Friday of each week on a 28-day cycle

20 mg a day,

CR 22.2%, PR 44.4%, SD 11.1%, POD 22.2%



Castration-resistant prostate cancer (16)

Arm I: 20 mg on 1,3 and 5 for 2 weeks on a 28-day cycle; Arm II: 15 mg on 1,3 and 5 for 2 weeks on a 28-day cycle with docetaxel and prednisone

Arm I: POD 100%; arm II: PR 37.5%



Advanced CTCL(stage IB-IVA)

Group 1 previously treated with bexarotene(25); group 2 bexarotene naïve(15)

Days 1,3, and 5 weekly until disease progression or intolerance

Group 1:

PR12%, SD16%, PD12%;other patients and most patients in groups have had less than 2 months of follow-up.